NCT03078010View on ClinicalTrials.gov

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

347

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Intestinal MicrobiomeFebrile Neutropenia
Interventions
DRUG

Piperacillin-tazobactam

piperacillin-tazobactam (4.5 gm IV q 6 hrs)

DRUG

cefepime

(2 gm IV q 8 hrs)

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

07601

Hackensack Meridian Health, Hackensack

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER